Impact of the number of repeated inhalations and patient characteristics on the residual amount of inhaled laninamivir octanoate hydrate dry powder in pediatric patients with influenza

• Main Authors: Toshiki Murasaka (Author), Kenji Ikemura (Author), Tomoyuki Enokiya (Author), Yuichi Muraki (Author), Mayumi Ikemura (Author), Koji Terada (Author), Takuya Iwamoto (Author), Masahiro Okuda (Author)
• Format: Book
• Published: BMC, 2017-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background A dry powder inhaled formulation is used for the anti-influenza drug laninamivir octanoate hydrate (laninamivir). Although two successive inhalations (puffs) are recommended to minimize residual amounts of active ingredients, previous reports suggest that pediatric patients with...